A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

• Status: Terminated
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Morphotek

Criteria

Inclusion Criteria:

• Measurable metastatic melanoma that has failed standard therapy

• Males and females greater than or equal to 18 years of age

• Life expectancy of greater than or equal to 3 months

Exclusion Criteria:

• Significant cardiovascular impairment

• Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results

• Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028